钇-90放射栓塞作为肝移植前桥接治疗较化疗栓塞降低等待名单脱落风险
基于UNOS数据库5677例肝移植等待者,比较TARE与TACE作为HCC一线局部区域治疗的等待名单结局;TARE组1年、2年、3年等待名单脱落累积发生率分别为8.9%、14.2%、16.8%,均低于TACE组的11.4%、19.0%、22.1%,且TARE组完全坏死率更高、仅需一次治疗比例更高。
要点
- TARE较TACE降低22%等待名单脱落风险(HR 0.78,95%CI 0.69-0.89,p<0.001)。
- TARE组仅一次局部治疗比例80.6%,高于TACE组57.8%。
- TARE组移植肝完全坏死率35.3%,高于TACE组20.2%。
核心结论
- 在HCC肝移植等待者中,TARE作为一线局部区域治疗较TACE与更高的完全坏死率、更少的多次治疗需求及更低的等待名单脱落风险相关。
主要发现
- TARE组初始单发肿瘤比例76.4%,高于TACE组70.5%;总肿瘤负荷相似。
- TARE组仅接受一次局部治疗比例80.6%,高于TACE组57.8%;移植肝完全坏死率35.3%,高于TACE组20.2%。
- 在逆概率治疗加权竞争风险分析中,调整患者和肿瘤特征后,TARE与等待名单脱落风险降低22%相关(HR 0.78,95%CI 0.69-0.89,p<0.001)。
- 等待名单脱落累积发生率TARE组1年8.9%、2年14.2%、3年16.8%,TACE组分别为11.4%、19.0%、22.1%。
临床怎么用
- 对于符合移植标准的HCC等待者,TARE可作为优于TACE的桥接治疗选择,以更好地维持肿瘤分期并降低等待名单脱落风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Recent small studies suggest improved hepatocellular carcinoma (HCC)-related outcomes with transarterial radioembolization (TARE) compared with transarterial chemoembolization (TACE), although it is unclear whether this translates into superior transplant-related outcomes. We aimed to compare waitlist outcomes for TARE vs. TACE as first-line locoregional treatment (LRT) for HCC in the contemporary MMaT (median MELD at transplant minus 3) era, with standardized wait times nationwide. METHODS: The study cohort comprised 5,677 adult liver transplant candidates from the United Network for Organ Sharing database who had at least one approved HCC exception between May 14, 2019, and October 3, 2024, and received first-line LRT with either TACE (50.0%) or TARE (50.0%). RESULTS: The TARE group had a slightly higher proportion of patients with solitary initial tumors (76.4% vs. 70.5%) and a slightly larger median largest tumor size, although total tumor burden was similar. A higher proportion of patients in the TARE group received only one LRT (80.6% vs. 57.8%) and achieved complete necrosis on explant (35.3% vs. 20.2%) compared with the TACE group. In inverse probability of treatment-weighted competing risk analysis, TARE was associated with a 22% lower hazard of waitlist dropout (hazard ratio 0.78, 95% CI 0.69-0.89, p <0.001; cumulative incidence at 1 year: 8.9% vs. 11.4%; 2 years: 14.2% vs. 19.0%; 3 years: 16.8% vs. 22.1%), after adjusting for patient and tumor characteristics. CONCLUSIONS: In a large national cohort of liver transplant candidates with HCC, TARE as first-line LRT was associated with higher rates of complete necrosis on explant, lower likelihood of requiring multiple LRTs, and a lower risk of waitlist dropout compared with TACE. IMPACT AND IMPLICATIONS: With nearly all patients with hepatocellular carcinoma in the US now receiving locoregional therapies, a better understanding of the optimal type of locoregional therapy to achieve tumor control and maintain tumor stage within transplant criteria is needed. In this contemporary study of over 5,000 patients using the US national database (UNOS), we show that transarterial radioembolization (TARE) may be the preferred bridging therapy over chemoembolization (TACE), based on a significantly lower probability of waitlist dropout after controlling for liver function and tumor characteristics. Additionally, TARE-treated patients demonstrated higher probability of complete pathologic response and reduced tumor under-staging on explant, which taken together strongly suggests that TARE is a more effective tumor treatment than TACE.
引用
- Kim NG, Yao FY, Kwong AJ, et al. Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma. J Hepatol. 2026. PMID: 41580092. doi:10.1016/j.jhep.2026.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。